Let me say right off that I am a brilliant, highly successful person with lots of advisers and experts at my beck and call, not to mention servants, lackeys, and highly trained seals. In fact,you can consider me a financial ringmaster (in Latin, ringo mastera; in German, ringe meister). Now that I have impressed you with my book learnin',and overall mastery of the universe, let's talk a little about NWBO. No one on this board knows enough astrology to predict whether dc vax will be successful in phase 3. Fortunately, I have consulted with the Wizard of Oz and Harry Potter, and I have some answers, Unfortunately, I cannot share them with you at this time
Something stinks beyond lack of growth prospects or even AR issues. I am a "bagholder" and embarassed I didn't pay attention to the stock price action, very negative since $7.75 a share.
thanks, saw that on tr\anscript of CC. Not very forthcoming except they indicate little visibility, much competition, pricing pressure. But surely they have cash flow to pay dividend. Do they want to or to buy back shares, cheaper then to buy out Co.? They have too much capacity, utilizing 40% of new plant, will utilize more, but then will be utilizing less of other plants. The resin transformers are a commodity. Stock still looks cheap, but I can''t buy more
literally and figuratively. speculation about co. welcome at this point. what is the other shoe and when will it drop? Is no mention of the dividend an attempt to drive the sp lower and buy cheaper?
it has to infringe on ivacator patent, you can't make a long acting version of a drug and claim it is entirely new or "new enough' . It is possibleif it works better, Vertex agrees to work with them and not fight them.
Tivo met its primary endpoint and there was not significant difference between the drugs on OS. Any small tendency for beva being better on OS was negated by the flawed design that gave beva the advantage. That being said, retaining the CEO for so long and now making him CB after this flawed trial is an outrage. Termeer should be ashamed of himself.
who's clueless, you arrogant, pumping dud? First, google amd and HIV drugs, and you will find that they have only been tried on mice so far in terms of AMD. Ashton clearly said that he has not even initiated pre-clinical trials with repurposed drugs. You are talking years before this even enters proof of concept trials. Still no word on Avastin preclincally, other than the usual, diffuse, "things are going well, we are making great progress" speech. As for Illuvien, Ashton said clearly not to look for any significant or maybe even any revenue this year. The company has promise, but so far more sizzle than steak. We'll see.